Atty. Docket No. PG4787USw

DT12 Rec'd PCT/PTO 27 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Appl	lication of Rachael Ann ANCLIFF et al.									
Serial No.: T	To be assigned	Art Unit:								
Filing Date:	Concurrently herewith	Examiner:								
For: Anti-	i-inflammatory Morpholin- tamide Derivatives									
P.O. Box 14	ner for Patents 150 , VA 22313-1450									
INFORMATION DISCLOSURE STATEMENT										
Applicants r Examiner ar	request that the references identified on Form PT and officially made of record in accordance with t	O-1449 appended hereto be considered by the he provisions of 37 CFR 1.97								
577 C	in a father references listed on the attached form	n PTO-1449 as item nos. 4-16, 18-22, 24,-and 26-32 are								
end [] Co [X] A	closed pies of the references were submitted in parent a copy of the International Search Report which is	application Serial No (37 CFR 1.98(d)) issued on International Application No. All of the publications cited in the International Search is item nos. 3, 17, 23 and 25, and Applicants understand								
A. [X]	The Information Disclosure Statement su	bmitted herewith is being filed within three months of the te of entry into the national stage of an international a first Office action on the merits, whichever event								
OR []	The Design of the Company	submitted herewith is being filed before the mailing fa Request For Continued Examination under 37								
В. []	filing date of the above application or the da an international application or after the mailing event occurred last, but before the mailing da (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311 whichever occurs first.	,								
[]	Statement was cited in a communication from application not more than three months prior									
[]	Applicant elects the option to pay the fee set	forth in 37 CFR 1.17(p) for submission of an Information								

Disclosure Statement under § 1.97(c) (\$180.00).

10/509341 PF12 Rec'd PCT/PTO 27 SEP 2004

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek
Attorney of Record

Registration No. 39,009

Date: September 24, 2004

GlaxoSmithKline

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

Page 1 of 2 112 Recid PCTAPTO ATTORNEY DOCKET NO. **FORM PTO-1449** To be assigned PG4787USw INFORMATION DISCLOSURE STATEMENT APPLICANT Rachael Ann ANCLIFF et al. GROUP FILING DATE Concurrently herewith **U.S. PATENT DOCUMENTS** Filing Date If Appropriate Subclass Class Name **Issue Date** Patent Examiner Initials Number OLSON 02/14/1995 5,389,635 02/29/2000 HE et al. 6,031,097 2. Continue on page FOREIGN PATENT DOCUMENTS Translation Publication Yes | No Document Subclass Class Country Date Number 11/04/1987 **EPO** EP 0243959 3. $\overline{\mathbf{x}}$ **EPO** 03/08/1989 EP 0306440 4. $\overline{\mathbf{x}}$ WIPO 11/30/1995 WO 95/32196 5. $\overline{\mathbf{x}}$ 12/14/1995 WIPO WO 95/33724 X (Abstract) 6. WIPO 02/01/1996 WO 96/02534 7. $\overline{\mathbf{x}}$ WIPO 12/12/1996 WO 96/39386 8. X (Abstract) WIPO 12/18/1997 WO 97/47601 9 X WIPO 12/17/1998 WO 98/56771 10. Continue on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Bedford et al., "Nonquaternary cholinesterase reactivators. 3. 3(5)-substituted 1,2,4-oxadiazol-5(3)aldoximes and 1,2,4-oxadiazole-5(3)-thiocarbohydroximates as reactivators of organophosphonate-inhibited eel and human acetylcholinesterase in vitro," Journal of Medicinal Chemistry 29(11):2174-2183 (Nov. Branco et al., "Reactions of hydroxylamines with ethyl cyanoformate. Preparation of aminonitrones and their 12. synthetic applications," Tetrahedron 48(30):6335-6360 (1992). Gakh et al., "N-fluorination with cesium fluoroxysulfate," Tetrahedron 47(35):7447-7458 (Aug. 1991). Gonzalo et al., "The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and 13. airway hyperresponsiveness," J. Exp. Med. 188(1):157-167 (Jul. 1998). 14 Heath et al., "Chemokine receptor usage by human eosinophils," J. Clin. Invest. 99(2):178-184 (1997). Jose et al., "Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic 15. 16. airways inflammation," J. Exp. Med. 179(3):881-887 (Mar. 1994). Kato et al., "Novel benzamides as selective and potent gastric prokinetic agents 2.. Synthesis and structureactivity relationships of 4-Amino-5-Chloro-2-Ethoxy-N-4-(4-Fluorobenzyl)-2-Morpholinyl 17. Methylbenzamide Citrate (AS-4370) and related compounds," Journal of Medicinal Chemistry 34(2):1616-

EXAMINER DATE CONSIDERED

624 (Feb. 1991).

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Continue on page 2



UTIZ Racid PCT/PTO 27 Page 2 of 2

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. SERVAT NOO 3 4 1 PG4787USw To be assigned			19341			
					APPLICANT					
					Rachael Ann ANCLIFF et al.					
· · · · · · · · · · · · · · · · · · ·					FILING DATE		GROUP			
				Concurrently he	rewith					
U.S. PATENT DOCUMENTS										
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate		
							-			
						Ì				
						Ì				
								-		
			Co	ontinue on p	age					
-			FOREIGN PA	TENT DO	CUMENTS (Cont	t'd)				
		Document	Publication					Translation		
		Number	Date		Country	Class	Subclass	Yes No		
	18.	WO 99/06384	02/11/1999	WIPO				X		
	19.	WO 99/21848	05/06/1999	WIPO				X		
	20.	WO 00/06606	02/10/2000	WIPO				X		
	21.	WO 00/18767	04/06/2000	WIPO				X		
	22.	WO 00/69830	11/23/2000	WIPO				X		
	23.	WO 00/71518	11/30/2000	WIPO				X		
	24.	WO 01/24786	04/12/2001	WIPO				X (Abstract)		
	25.	WO 02/26722	04/04/2002	WIPO				X		
				ontinue on p						
		HER DOCUMEN								
	26.	Krein et al., "Phase transfer-catalyzed reactions between polysulfide anions and α,β-unsaturated carbonyl compounds," Journal of Organic Chemistry 58(22):6103-6108 (Oct. 1993).								
•	27.	Lazareno et al., "Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations," Br. J. Pharmacol 109:1110-1119 (1995).								
	28.							ed chemokine in		
	20.	Lloyd et al., "CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocype type 2 recruitment after serial antigen challenge in vivo," <i>J. Exp. Med.</i> 191(2):265-273 (Jan. 2000).								
	29.	Luster, "Chemokines – chemotactic cytokines that mediate inflammation," New England Journal of Medicine								
		338(7):436-445 (Feb. 1998).								
	30.	Mack et al., "Drug-induced modifications of the immune response. 12. 4,5-dihydro-4-oxo-2-(substituted								
		amino)-3-furancarboxylic acids and derivatives as novel antiallergic agents," Journal of Medicinal Chemistry 31(10):1910-1918 (Oct. 1988).								
	31.	Wells et al., "Plag	giarism of the hos	t immune s	ystem: lessons abou	ut chemokine i	mmunology f	rom viruses,"		
		Curr. Opin. Biote								
	32.	Wong-Lun-Sang et al., "Bacterial siderophores: Structure elucidation, 2D ¹ H and ¹³ C NMR assignments of pyoverdins produced by <i>Pseudomonas fluorescens</i> CHAO," <i>Tetrahedron Letters</i> 37(19) :3339-3342 (May								
1996).										
EV. 1			C	ontinue on	page	T = · == :				
EXAMINER	•					DATE	CONSIDERE	D		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through										
citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.										